Summary of Project Groups


¡Ø PGRC database¿¡ µî·ÏµÈ ÇÁ·ÎÁ§Æ®(project) Áß °øÅëÀÇ Áúº´ ¹× ¾à¹°¿¡ °üÇÑ ¿¬±¸µéÀ» ¸ð¾Æ¼­ ±×·ì(group)È­ÇÑ µ¥ÀÌÅÍ Á¤º¸ÀÔ´Ï´Ù.
¡Ø ÇÁ·ÎÁ§Æ®(project) Á¤º¸¿¡ °üÇÑ ¹®ÀÇ»çÇ×Àº ÇÁ·ÎÁ§Æ®°ü¸®ÀÚ(selkie@inje.ac.kr) ¹× Á¤º¸°ü¸®´ã´çÀÚ(pgrcdb@gmail.com)¿¡°Ô ¿¬¶ô Áֽñ⠹ٶø´Ï´Ù.

Ç÷¾×¾Ï : [Blood Cancer Site link]
Project Code IRB Code Á¦¸ñ ¸ñÀû ¹× °³¿ä Ã¥ÀÓ¿¬±¸ÀÚ
P09-085 09-029 Ç÷¾×¾Ï ¸ÂÃãÄ¡·á¸¦ À§ÇÑ »ýüÁöÇ¥°³¹ß ¿¬±¸ ½ÅÀç±¹
P09-025 09-029 Identification of small molecule CK2 inhibitor ¿À»óÅÃ
P09-026 09-029 Interactomics identifies that 14-3-3a modulate PXR activity through their interaction ¿À»óÅÃ
P09-045 09-029 Ç÷¾×¾Ï¿¡¼­ Ç×¾ÏÄ¡·á È¿°ú¿Í ¼¼Æ÷Áß ¾à¹°³óµµÀÇ »ó°ü°ü°è ¿¬±¸ ¹× ±âÀü ¿¬±¸ drug uptake study, drug sensitivity study, gene expression ¼ÛÀÓ¼÷
P09-066 09-029 Association between Epigenetic Alteration and Chemotherapy Response in Blood Cancer Ç÷¾×¾Ï ȯÀÚ¿¡¼­ Ç×¾ÏÁ¦ Ä¡·á Àü°ú Ä¡·á ÈÄ ÃßÀû °üÂû½Ã °ñ¼ö¼¼Æ÷ ¹× Ç÷¾× DNAÀÇ methylation profileÀ» ¹ÝÀÀ±º°ú ºñ¹ÝÀÀ±º¿¡¼­ ºñ±³, ºÐ¼®ÇÏ¿© Ç÷¾×¾ÏÀÇ Ç×¾ÏÁ¦ ³»¼º ±âÀüÀ¸·Î¼­ epigenetic factorÀÇ ¿ªÇÒÀ» ±Ô¸íÇÑ´Ù. ÃÖÁö¿±


Warfarin : [Warfarin Site link] / [Warfarin Dosing Site link] / [OpenClinica Site link]
Project Code IRB Code Á¦¸ñ ¸ñÀû ¹× °³¿ä Ã¥ÀÓ¿¬±¸ÀÚ
P09-071 09-025 ¿ÍÆÄ¸° ÀûÀÀÁõ È®´ë ¿ÍÆÄ¸°D/B±¸Ãà ¹× Á¤»ó»óÅ ÃÖÀû¿ë·® ¿¹Ãø¸ðµ¨¸¶·Ã ½ÅÀç±¹
P09-030 09-025 Genetic polymorphisms of CYP2C9 in Koreans and their associations with warfarin sensitivity To provide distributions of CYP2C9 polymorphisms in Koreans and to analyze the relationship between CYP2C9 genetic variant and warfarin sensitivity À̼öÁØ
P09-032 09-025 Genetic polymorphismsof CYP4F2 and their effects on warfarin sensitivity To provide distributions of CYP4F2 polymorphisms in Koreans and to investigate the effects of CYP4F2 variants on wafarin dose requirement in the patients with mechanical heart valve replacement À̼öÁØ


Breast Cancer
Project Code IRB Code Á¦¸ñ ¸ñÀû ¹× °³¿ä Ã¥ÀÓ¿¬±¸ÀÚ
09-140 TamoxifenÀÇ ¾à¹°¹ÝÀÀ ¹× ¿¹ÈÄ¿¡ °ü·ÃµÈ »ýüÁöÇ¥°³¹ß À¯¹æ¾Ï ½ÅÀç±¹
P09-090 À¯¹æ¾Ï ¾à¹°³»¼ºÀÇ À¯Àüü ¿¬±¸ À¯¹æ¾Ï ¼¼Æ÷ÁÖ¸¦ ÀÌ¿ëÇÑ Å¸¸ñ½ÃÆæ, Ç×¾ÏÁ¦ ¾à¹°³»¼ºÀÇ ºÐÀÚÀû ±âÀü¿¡ ´ëÇØ ÁÖ¿äÇÑ ÀÛ¿ë°æ·Î ¶Ç´Â ÁöÇ¥¸¦ ¹ß±¼. ÀÌ»ó¼·
P09-077 ¿¬¼¼´ë °øµ¿ Global methylation level in leukocyte and chemoresistance in breast cancer treatment À¯¹æ¾Ï ȯÀÚ±º¿¡¼­ ¹éÇ÷±¸ DNAÀÇ global methylation Á¤µµ°¡ Ç×¾ÏÁ¦ ³»¼ºÀÇ °á°ú·Î¼­ ¾ÏÀÇ Àç¹ß·ü ¶Ç´Â »ýÁ¸·ü¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ ÃÖÁö¿±
P09-084 ¿¬¼¼´ë °øµ¿ Clinical implications of CYP3A5, CYP2C19 and CYP2D6 genetic polymorphisms in tamoxifen treatment for breast cancer among Asian women We investigated the prognostic and/or predictive value of genetic polymorphisms of CYP3A5, CYP2C19 and CYP2D6 for tamoxifen treatment outcome among Asian breast cancer patients. ½ÅÀç±¹


Epilepsy
Project Code IRB Code Á¦¸ñ ¸ñÀû ¹× °³¿ä Ã¥ÀÓ¿¬±¸ÀÚ
05-075 ³­Ä¡¼º °£Áú ¿¹Ãø ¸ðµ¨ °³¹ßÀ» À§ÇÑ µ¿³²±Ç °£Áú¿¬±¸ ³×Æ®¿öÅ© ±¸Ãà(Epilepsy) ³­Ä¡¼º °£ÁúÀ» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ÀÓ»óÀû, À¯ÀüÀû ¿äÀο¡ ´ëÇÑ ¿¬±¸ ½ÅÀç±¹
P09-053 05-075 Epilepsy_simultaneous determination using LC-MS/MS techniques ¹è¼ö°æ
P09-083 05-075 Multigenetic approach to predict lamotrigine response in Epileptic patients We aimed to predict lamotrigine response on the treatment of epilepsy by multigenetic approach involving in genes of pharmacokinetics (ABCB1, UGT1A4) and pharmacodynamics (SCN1A) of lamotrigine ½ÅÀç±¹